$Akebia Therapeutics(AKBA)$1st_老虎社区_美港股上老虎 - 老虎社区

$Akebia Therapeutics(AKBA)$1st for treatment for CKD after FDA disapprove FGEN roxa. 👍

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

沙漠追光大海逐风
2021-08-17
沙漠追光大海逐风
能买吗？看了一眼这股主业，应该是黄金赛道呀，一起买？
宝宝金水_
2021-08-17
宝宝金水_
基于缺氧诱导因子的新型生物性专有疗法的研发，肾脏疾病患者所需产品商业化应用的生物制药公司。HIF是人体内红细胞生成和潜在贫血治疗新机制的主要调节器。Akebia的候选主导产品AKB-6548作为一种每日一次的口服产品，已经成功完成2a期概念验证。研究表明AKB-6548可以在不需要透析的情况下安全有效地提高继发性贫血和慢性肾病患者的血红蛋白水平。这种技术应该有很大的市场。
哎呀呀小伙子
2021-08-17
哎呀呀小伙子
Akebia Therapeutics, Inc.依法于2007年2月27日在特拉华州成立。该公司是一家致力于：基于缺氧诱导因子的新型生物性专有疗法的研发，肾脏疾病患者所需产品商业化应用的生物制药公司。HIF是人体内红细胞生成和潜在贫血治疗新机制的主要调节器。Akebia的候选主导产品AKB-6548作为一种每日一次的口服产品，已经成功完成2a期概念验证。研究表明AKB-6548可以在不需要透析的情况下安全有效地提高继发性贫血和慢性肾病患者的血红蛋白水平。基本面看着可以呀，怎么会是这个走势？
老夫追涨杀跌
2021-08-17
老夫追涨杀跌
技术指标还是欠佳呀，K线图看着很是难看，总感觉不到底。
搞钱树
2021-08-17
搞钱树
FDA不批准FGEN ROXA，有这么大的影响力吗？不科学呀？

发表看法

6

1

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":833065147,"tweetId":"833065147","gmtCreate":1629190115989,"gmtModify":1631890925272,"author":{"id":4089582726645360,"idStr":"4089582726645360","authorId":4089582726645360,"authorIdStr":"4089582726645360","name":"justtotrade","avatar":"https://static.tigerbbs.com/f0fda6e146d2e7cc16d62cb1336a466d","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":7,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p><a href=\"https://laohu8.com/S/AKBA\">$Akebia Therapeutics(AKBA)$</a>1st for treatment for CKD after FDA disapprove FGEN roxa. 👍</p></body></html>","htmlText":"<html><head></head><body><p><a href=\"https://laohu8.com/S/AKBA\">$Akebia Therapeutics(AKBA)$</a>1st for treatment for CKD after FDA disapprove FGEN roxa. 👍</p></body></html>","text":"$Akebia Therapeutics(AKBA)$1st for treatment for CKD after FDA disapprove FGEN roxa. 👍","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":6,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/833065147","repostId":0,"isVote":1,"tweetType":1,"viewCount":210,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["AKBA"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":76,"xxTargetLangEnum":"ORIG"},"commentList":[{"id":5554624,"commentId":"5554624","gmtCreate":1629191904871,"gmtModify":1629191904871,"authorId":9000000000000220,"author":{"id":9000000000000220,"idStr":"9000000000000220","authorId":9000000000000220,"name":"沙漠追光大海逐风","avatar":"https://static.tigerbbs.com/e30b7f24ce0a6599dcdfa3567f958dea","vip":8,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":833065147,"objectIdStr":"833065147","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"能买吗？看了一眼这股主业，应该是黄金赛道呀，一起买？","text":"能买吗？看了一眼这股主业，应该是黄金赛道呀，一起买？","html":"能买吗？看了一眼这股主业，应该是黄金赛道呀，一起买？","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0,"disclaimerType":0},{"id":5554610,"commentId":"5554610","gmtCreate":1629191810186,"gmtModify":1629191810186,"authorId":9000000000000159,"author":{"id":9000000000000159,"idStr":"9000000000000159","authorId":9000000000000159,"name":"宝宝金水_","avatar":"https://static.tigerbbs.com/3277b62086966882a8b4e45d9f8b88bb","vip":8,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":833065147,"objectIdStr":"833065147","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"基于缺氧诱导因子的新型生物性专有疗法的研发，肾脏疾病患者所需产品商业化应用的生物制药公司。HIF是人体内红细胞生成和潜在贫血治疗新机制的主要调节器。Akebia的候选主导产品AKB-6548作为一种每日一次的口服产品，已经成功完成2a期概念验证。研究表明AKB-6548可以在不需要透析的情况下安全有效地提高继发性贫血和慢性肾病患者的血红蛋白水平。这种技术应该有很大的市场。","text":"基于缺氧诱导因子的新型生物性专有疗法的研发，肾脏疾病患者所需产品商业化应用的生物制药公司。HIF是人体内红细胞生成和潜在贫血治疗新机制的主要调节器。Akebia的候选主导产品AKB-6548作为一种每日一次的口服产品，已经成功完成2a期概念验证。研究表明AKB-6548可以在不需要透析的情况下安全有效地提高继发性贫血和慢性肾病患者的血红蛋白水平。这种技术应该有很大的市场。","html":"基于缺氧诱导因子的新型生物性专有疗法的研发，肾脏疾病患者所需产品商业化应用的生物制药公司。HIF是人体内红细胞生成和潜在贫血治疗新机制的主要调节器。Akebia的候选主导产品AKB-6548作为一种每日一次的口服产品，已经成功完成2a期概念验证。研究表明AKB-6548可以在不需要透析的情况下安全有效地提高继发性贫血和慢性肾病患者的血红蛋白水平。这种技术应该有很大的市场。","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0,"disclaimerType":0},{"id":5554604,"commentId":"5554604","gmtCreate":1629191737989,"gmtModify":1629191737989,"authorId":9000000000000158,"author":{"id":9000000000000158,"idStr":"9000000000000158","authorId":9000000000000158,"name":"哎呀呀小伙子","avatar":"https://static.tigerbbs.com/df6a0fed4b2624034014be633476534a","vip":8,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":833065147,"objectIdStr":"833065147","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"Akebia Therapeutics, Inc.依法于2007年2月27日在特拉华州成立。该公司是一家致力于：基于缺氧诱导因子的新型生物性专有疗法的研发，肾脏疾病患者所需产品商业化应用的生物制药公司。HIF是人体内红细胞生成和潜在贫血治疗新机制的主要调节器。Akebia的候选主导产品AKB-6548作为一种每日一次的口服产品，已经成功完成2a期概念验证。研究表明AKB-6548可以在不需要透析的情况下安全有效地提高继发性贫血和慢性肾病患者的血红蛋白水平。基本面看着可以呀，怎么会是这个走势？","text":"Akebia Therapeutics, Inc.依法于2007年2月27日在特拉华州成立。该公司是一家致力于：基于缺氧诱导因子的新型生物性专有疗法的研发，肾脏疾病患者所需产品商业化应用的生物制药公司。HIF是人体内红细胞生成和潜在贫血治疗新机制的主要调节器。Akebia的候选主导产品AKB-6548作为一种每日一次的口服产品，已经成功完成2a期概念验证。研究表明AKB-6548可以在不需要透析的情况下安全有效地提高继发性贫血和慢性肾病患者的血红蛋白水平。基本面看着可以呀，怎么会是这个走势？","html":"Akebia Therapeutics, Inc.依法于2007年2月27日在特拉华州成立。该公司是一家致力于：基于缺氧诱导因子的新型生物性专有疗法的研发，肾脏疾病患者所需产品商业化应用的生物制药公司。HIF是人体内红细胞生成和潜在贫血治疗新机制的主要调节器。Akebia的候选主导产品AKB-6548作为一种每日一次的口服产品，已经成功完成2a期概念验证。研究表明AKB-6548可以在不需要透析的情况下安全有效地提高继发性贫血和慢性肾病患者的血红蛋白水平。基本面看着可以呀，怎么会是这个走势？","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0,"disclaimerType":0},{"id":5554630,"commentId":"5554630","gmtCreate":1629191960225,"gmtModify":1629191960225,"authorId":3479274702625278,"author":{"id":3479274702625278,"idStr":"3479274702625278","authorId":3479274702625278,"name":"老夫追涨杀跌","avatar":"https://static.tigerbbs.com/53d8be38e6bbbfa27d16721be9a4e59b","vip":8,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":833065147,"objectIdStr":"833065147","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"技术指标还是欠佳呀，K线图看着很是难看，总感觉不到底。","text":"技术指标还是欠佳呀，K线图看着很是难看，总感觉不到底。","html":"技术指标还是欠佳呀，K线图看着很是难看，总感觉不到底。","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0,"disclaimerType":0},{"id":5554618,"commentId":"5554618","gmtCreate":1629191870248,"gmtModify":1629191870248,"authorId":9000000000000221,"author":{"id":9000000000000221,"idStr":"9000000000000221","authorId":9000000000000221,"name":"搞钱树","avatar":"https://static.tigerbbs.com/82edc4968feb7c0c481f5ad38d9a498b","vip":8,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":833065147,"objectIdStr":"833065147","type":1,"supId":0,"supIdStr":"0","prevId":0,"prevIdStr":"0","content":"FDA不批准FGEN ROXA，有这么大的影响力吗？不科学呀？","text":"FDA不批准FGEN ROXA，有这么大的影响力吗？不科学呀？","html":"FDA不批准FGEN ROXA，有这么大的影响力吗？不科学呀？","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0,"disclaimerType":0}],"isCommentEnd":false,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/833065147"}